VIRX
Viracta Therapeutics, Inc.Company Information
- Company Name
- Viracta Therapeutics, Inc.
- CIK
- CIK0001061027
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VIRX: None
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VIRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-01
- Last sale
- 2024-02-27
- Shares purchased (TTM)
- 47,906
- Shares sold (TTM)
- 20,027
Institutional Sentiment
- As of
- 2024-12-31
- Institutional shares owned
- 3,391,371
- Shares outstanding
- 39,574,070
- Ownership
- 8.57%
Earnings Market Reaction
- Filing date
- 2024-11-13
- Price on filing date
- —
- 1-month reaction
- 0.25%
- 3-month reaction
- -3.56%
Balance Sheet
Values in millions ($)| Line item | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 14 | 12 | 12 | 13 | 14 | 18 | 37 | 23 | 82 | 92 | 104 | ||||||
| Short Term Investments | 8 | 16 | 28 | 41 | 50 | 59 | 62 | 54 | 54 | 2 | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Assets Current | 22 | 31 | 41 | 55 | 64 | 75 | 83 | 94 | 80 | 86 | 95 | 105 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 22 | 31 | 41 | 57 | 66 | 77 | 86 | 96 | 82 | 89 | 98 | 109 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | ||||||
| Accrued Liabilities Current | 10 | 9 | 9 | 10 | 9 | 7 | 7 | 7 | 7 | 5 | 4 | 6 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Long Term Debt Current | - | - | - | 25 | 25 | 4 | 2 | 0 | - | - | - | - | ||||||
| Debt Current | 17 | 19 | 19 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 29 | 29 | 30 | 38 | 36 | 15 | 12 | 10 | 9 | 7 | 8 | 9 | ||||||
| Long Term Debt Noncurrent | - | - | - | 0 | 0 | 21 | 23 | 25 | 5 | 5 | 5 | 5 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Long Term Debt | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Liabilities | 29 | 29 | 30 | 38 | 36 | 36 | - | 35 | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 289 | 282 | 281 | 279 | 277 | 275 | 273 | 271 | 267 | 258 | 256 | 255 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | - | - | 0 | ||||||
| Retained Earnings Accumulated Deficit | -295 | -285 | -275 | -266 | -252 | -240 | -227 | -215 | -205 | -187 | -176 | -166 | ||||||
| Stockholders Equity | -7 | 3 | 11 | 18 | 30 | 41 | 51 | 61 | 68 | 77 | 86 | 94 | ||||||
| Liabilities And Stockholders Equity | 22 | 31 | 41 | 57 | 66 | 77 | 86 | 96 | 82 | 89 | 98 | 109 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 40 | 39 | 39 | 39 | 39 | 39 | 38 | 38 | 38 | 38 | 37 | 37 | ||||||
| Shares Outstanding | 40 | 39 | 39 | 39 | 39 | 39 | 38 | 38 | 38 | 38 | 37 | 37 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialViracta Therapeutics, Inc. (VIRX) — SEC Financial Statements & Analysis
Viracta Therapeutics, Inc. (VIRX) is a pharmaceutical preparations company, incorporated in DE. Viracta Therapeutics, Inc. trades on None as: VIRX. Viracta Therapeutics, Inc. (VIRX)'s most recent SEC filing is a Form 10-Q for the period ended 2024-09-30, filed with the SEC on 2024-11-13. Based on that filing, On profitability, Viracta Therapeutics, Inc. posts a Return on Equity (ROE) of -370.13%, a Return on Assets (ROA) of -97.94%, and a Return on Invested Capital (ROIC) of -180.94%. Per share, it reports EPS of $-1.09, diluted EPS of $-1.09, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -9.09% year-over-year, and EPS growth of -11.14% year-over-year. On the balance sheet, it maintains a current ratio of 0.76x, a quick ratio of 0.74x, working capital of $-6.77M, a debt-to-equity ratio of -4.32x, a debt ratio of 1.3, an interest coverage ratio of -14.83x, free cash flow of $-34.80M (TTM), and net debt of $3.78M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.09
- ROE TTM
- -370.13%
- ROA TTM
- -97.94%
- Debt To Equity
- -4.32x
- Free Cash Flow TTM
- $-34.80M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2024-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Viracta Therapeutics, Inc. in?
Viracta Therapeutics, Inc. (VIRX) operates in the Pharmaceutical Preparations industry.
What exchange does VIRX trade on?
Viracta Therapeutics, Inc. (VIRX) trades on the None.
Where is Viracta Therapeutics, Inc. incorporated?
Viracta Therapeutics, Inc. is incorporated in DE.
When was Viracta Therapeutics, Inc. (VIRX)'s most recent SEC filing?
Viracta Therapeutics, Inc. (VIRX)'s most recent SEC filing is a Form 10-Q for the period ended 2024-09-30, filed with the SEC on 2024-11-13.
What is VIRX's EPS (earnings per share)?
Viracta Therapeutics, Inc. (VIRX)'s trailing twelve month EPS is $-1.09 as of 2024-09-30.
What is VIRX's ROE (return on equity)?
Viracta Therapeutics, Inc. (VIRX)'s trailing twelve month Return on Equity (ROE) is -370.13% as of 2024-09-30.
What is VIRX's ROA (return on assets)?
Viracta Therapeutics, Inc. (VIRX)'s trailing twelve month Return on Assets (ROA) is -97.94% as of 2024-09-30.
What is VIRX's ROIC (return on invested capital)?
Viracta Therapeutics, Inc. (VIRX)'s trailing twelve month Return on Invested Capital (ROIC) is -180.94% as of 2024-06-30.